olea europaea
AssetAlso Depigoid 50% Grasses/50% Olea europaea
Allergen extract immunotherapy for desensitization against olive pollen and grass allergy.
- Stage
- Phase 2
- Modality
- Other
- Target
- Not known
- 4
- Indications
- 1
- Trial
- 1
- Developer
Indications
4Allergy
Phase 2, Completed, NCT01734265, clinicaltrials.gov, 7 Oct 2026
Rhinitis
Phase 2, Completed, NCT01734265, clinicaltrials.gov, 7 Oct 2026
Rhinoconjunctivitis
Phase 2, Completed, NCT01734265, clinicaltrials.gov, 7 Oct 2026
1 more
In the full profile
- Owner and partners1
- Trials1
- Evidence for its targets1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 7 Oct 2026, 2 sources